Most of these symptoms improve over time as the body adapts, but they can be significant enough to cause discontinuation in some patients
The step-down process Once your weight has been stable for at least 4 weeks at your current dose, consider a gradual reduction
doi:10.1016/S2213-8587(25)00027-0
Reference standards supporting synthetic peptide quality
Biological Activity and Molecular Mass of Human Recombinant IGF-I LR3, ACF (A) The biological activity of Human Recombinant IGF-I LR3, ACF was tested by its ability to induce MAP/ERK signaling in transfected MCF-7 cells using a luciferase reporter assay
Kahn, MB, ChB, Professor of Metabolism, Endocrinology and Nutrition at the University of Washington (UW) and Veterans Affairs Puget Sound Health Care System, and Director of the UW Diabetes Research Center and the VA Puget Sound Diabetes Research Group